Dexamethasone therapy in very low birth weight infants at risk forchronic lung disease will have energy expenditure measured by CO2production, assessed by respiratory calorimetry and deuterium eliminationrates. The measurements will be made at 14 & 28 days.
Birth/Congenital Defects, Cardiology, Cardiovascular Diseases, Cystic Fibrosis, Diabetes, Endocrinology, Failure to Thrive, Lipoproteins, Metabolism, Metabolism, Amino Acid, Metabolism, Lipid, Metabolism, Protein, Neonatal Disorders, Nutrition/Dietetics, Obesity, Pediatrics
